Objectives: The aim of this study was to characterize the specific Epstein-Barr virus (EBV) polymorphisms from nasopharyngeal carcinoma (NPC) patients and healthy donors in Southern China, and to explore the relationship between EBV genotypes and NPC. Methods: The EBNA-2 gene of 32 EBV-positive NPCs and 39 EBV-positive throat washing (TW) samples from healthy individuals from Southern China was analyzed using PCR and sequencing. Results: We found E2-A to be the predominant subtype in Southern China. The distribution of EBNA-2 subtypes between NPCs and TWs was significantly different (p < 0.01) and the E2-A subtype was overly represented in NPCs. Conclusions: E2-A is the predominant subtype in Southern China, and the distribution of EBNA-2 subtypes between NPCs and TWs is significantly different. In Southern China, the E2-A subtype is significantly more frequent in NPCs than TWs, and is also more common than in Northern China. This suggests that the E2-A subtype may play an important role in the pathogenesis of NPC and that EBNA-2 gene variations are tumor-specific polymorphisms.

Keywords:
Nuclear antigen 2, Epstein-Barr virus, Nasopharyngeal carcinoma, Polymorphism
1.
Tsao SW, Tsang CM, To KF, Lo KW: The role of Epstein-Barr virus in epithelial malignancies. J Pathol 2015;235:323-333.
2.
Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG: The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015;235:312-322.
3.
Niller HH, Wolf H, Minarovits J: Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008;41:298-328.
4.
Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T: Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications. Cancer Epidemiol Biomarkers Prev 2008;17:2356-2365.
5.
Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1765-1777.
6.
Hsu JL, Glaser SL: Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000;34:27-53.
7.
Dawson CW, Eliopoulos AG, Blake SM, Barker R, Young LS: Identification of functional differences between prototype Epstein-Barr virus-encoded lmp1 and a nasopharyngeal carcinoma-derived lmp1 in human epithelial cells. Virology 2000;272:204-217.
8.
Fielding CA, Sandvej K, Mehl A, Brennan P, Jones M, Rowe M: Epstein-Barr virus lmp-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol 2001;75:9129-9141.
9.
Gutierrez MI, Raj A, Spangler G, Sharma A, Hussain A, Judde JG, Tsao SW, Yuen PW, Joab I, Magrath IT, Bhatia K: Sequence variations in EBNA-1 may dictate restriction of tissue distribution of Epstein-Barr virus in normal and tumour cells. J Gen Virol 1997;78:1663-1670.
10.
Gutierrez MI, Spangler G, Kingma D, Raffeld M, Guerrero I, Misad O, Jaffe ES, Magrath IT, Bhatia K: Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene. Blood 1998;92:600-606.
11.
Mai SJ, Ooka T, Li DJ, Zeng MS, Jiang RC, Yu XJ, Zhang RH, Chen SP, Zeng YX: Functional advantage of NPC-related V-val subtype of Epstein-Barr virus nuclear antigen 1 compared with prototype in epithelial cell line. Oncol Rep 2007;17:141-146.
12.
Murray PG, Young LS: The role of the Epstein-Barr virus in human disease. Front Biosci 2002;7:d519-d540.
13.
Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ: Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 1997;71:8552-8562.
14.
Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B: The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 1999;73:4481-4484.
15.
Weiss LM, Movahed LA: In situ demonstration of Epstein-Barr viral genomes in viral-associated B cell lymphoproliferations. Am J Pathol 1989;134:651-659.
16.
Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD: Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996;16:952-959.
17.
Henkel T, Ling PD, Hayward SD, Peterson MG: Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science 1994;265:92-95.
18.
Wang X, Wang Y, Wu G, Chao Y, Sun Z, Luo B: Sequence analysis of Epstein-Barr virus EBNA-2 gene coding amino acid 148-487 in nasopharyngeal and gastric carcinomas. Virol J 2012;9:49.
19.
Sugiura M, Imai S, Tokunaga M, Koizumi S, Uchizawa M, Okamoto K, Osato T: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 1996;74:625-631.
20.
Ikuta K, Satoh Y, Hoshikawa Y, Sairenji T: Detection of Epstein-Barr virus in salivas and throat washings in healthy adults and children. Microbes Infect 2000;2:115-120.
21.
Kwok H, Wu CW, Palser AL, Kellam P, Sham PC, Kwong DL, Chiang AK: Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol 2014;88:10662-10672.
22.
Walling DM, Perkins AG, Webster-Cyriaque J, Resnick L, Raab-Traub N: The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol 1994;68:7918-7926.
23.
Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, Zhang RH, Yu XJ, Wang HM, Ernberg I, Zeng YX: Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 2005;79:15323-15330.
24.
Walling DM, Raab-Traub N: Epstein-Barr virus intrastrain recombination in oral hairy leukoplakia. J Virol 1994;68:7909-7917.
25.
Hu LF, Qiu QH, Fu SM, Sun D, Magnusson K, He B, Lindblom A, Ernberg I: A genome-wide scan suggests a susceptibility locus on 5p13 for nasopharyngeal carcinoma. Eur J Hum Genet 2008;16:343-349.
26.
Xiong W, Zeng ZY, Xia JH, Xia K, Shen SR, Li XL, et al: A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res 2004;64:1972-1974.
27.
Guo X, Johnson RC, Deng H, Liao J, Guan L, Nelson GW, Tang M, Zheng Y, de The G, O'Brien SJ, Winkler CA, Zeng Y: Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. Int J Cancer 2009;124:2942-2947.
28.
Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature 2007;447:433-440.
29.
Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, Jia P, Assadzadeh A, Flanagan J, Schumacher A, Wang SC, Petronis A: Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008;82:696-711.
30.
Cohen JI, Wang F, Kieff E: Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 1991;65:2545-2554.
31.
Cohen JI, Kieff E: An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol 1991;65:5880-5885.
32.
Peng CW, Zhao B, Kieff E: Four EBNA2 domains are important for EBNALP coactivation. J Virol 2004;78:11439-11442.
33.
Cohen JI: A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci USA 1992;89:8030-8034.
34.
Chabot PR, Raiola L, Lussier-Price M, Morse T, Arseneault G, Archambault J, Omichinski JG: Structural and functional characterization of a complex between the acidic transactivation domain of EBNA2 and the Tfb1/p62 subunit of TFIIH. PLoS Pathog 2014;10:e1004042.
35.
Ling PD, Hayward SD: Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk. J Virol 1995;69:1944-1950.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.